THE GALIEN FOUNDATION

BEST PHARMACEUTICAL PRODUCT · PRIX GALIEN USA · NOMINEE 2021

PRODUCT: **Lutathera®**

COMPANY: Advanced Accelerator Applications

THERAPEUTIC AREA & INDICATION:
Radioactive isotope treatment for cancerous neuroendocrine tumors affecting the pancreas or gastrointestinal tract

ABOUT THE PRODUCT

LUTATHERA® (lutetium Lu 177 dotatate) is precision targeted therapy approved in the United States for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut and hindgut neuroendocrine tumors in adults[1]. LUTATHERA® belongs to a class of treatments called Peptide Receptor Radionuclide Therapy (PRRT), a type of radioligand therapy (RLT) that combines a radioactive particle with a targeting molecule that binds to a particular type of receptor (somatostatin) over-expressed by neuroendocrine tumors, inhibiting tumor growth and replication. The most common Grade 3-4 adverse reactions observed in LUTATHERA® clinical trials were lymphopenia (44%), increased GGT (20%), vomiting (7%), nausea (5%), elevated AST (5%), increased ALT (4%), hyperglycemia (4%), and hypokalemia (4%).1 Please see important Safety Information and Full Prescribing information at: LUTATHERA.US

1. LUTATHERA Prescribing Information: www.accessdata.fda.gov/drugsatfda_docs/label/2018/208700s000lbl.pdf